NEWSROOM

Press releases

July 6, 2022

Vaccizone selects Exothera for process development and GMP manufacturing of its SARS‑CoV‑2 vaccine based on proprietary ASC technology.

Read the press release

June 16, 2022

PAT4CGT Consortium Announces Prestigious €4.7M Pathfinder Grant Awarded by European Innovation Council for the Development of Modular Cell & Gene Therapy Manufacturing Platform

Read the press release

June 15, 2022

Exothera announces industrial scale AAV manufacturing collaboration with LogicBio Therapeutics and Polyplus

Read the press release

June 9, 2022

Exothera develops exoREADY, a ready-to-use viral vector production platform, to accelerate advanced therapy manufacture at scale 

Read the press release

April 12, 2022

ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle-Income Countries

Read the press release

March 31, 2022

Rokote Laboratories selects Exothera for GMP manufacturing of its second-generation coronavirus vaccine FINCoVac 2.0.

Read the press release

March 23, 2022

GMP certification for Exothera further expands its viral vector manufacturing capacity

Read the press release

March 1, 2022

IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines

Read the press release

October 27, 2021

Exothera announces the appointment of Hanna Lesch as Chief Technology Officer

Read the press release

September 9, 2021

GeneQuine selects Exothera to support the next stage of its osteoarthritis gene therapy development

Read the press release

July 1, 2021

Pall Corporation Secures Multi-Million Dollar Contract With Exothera

Read the press release

June 1, 2021

Univercells and Exothera announce Thibault Jonckheere as new CEO of Exothera

Read the press release

May 20, 2021

Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine Target with Global Public Health Demand

Read the press release

March 24, 2021

CyanVac selects Exothera for the development and GMP manufacturing of its COVID-19 intranasal vaccine candidate for phase III clinical trial in Europe and the US

Read the press release

January 28, 2021

Exothera completes its range of state-of-the-art technologies by acquiring the new generation of the NevoLine™ Upstream platform for its new site in Belgium

Read the press release

March 19, 2020

Univercells launches cell & gene therapy contract development and manufacturing organization (CDMO) Exothera with GMP capabilities in 15,000m² site in Jumet, Belgium

Read the press release